## SRPT: Sarepta Therapeutics, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.9% below STRENGTH zone (3.0-6.0%); PEG 159.25 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($18.40)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Assessing Sarepta Therapeutics (SRPT) Valuation After a Recent Share Price Rebound**
- Source: Simply Wall Street | 20251217T090912 | Neutral | Relevance: 100%
- Sarepta Therapeutics (SRPT) has seen a recent share price rebound of 18.61% over the last month, despite a challenging year where the stock is still down significantly. The company's valuation is complex, with a narrative model suggesting it's 9% overvalued, while its 1x price-to-sales ratio appears cheap compared to biotech peers. Analysts have a wide range of price targets for SRPT, highlighting disagreement on its future earnings growth and profitability.

**2. Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025**
- Source: ts2.tech | 20251216T160912 | Neutral | Relevance: 100%
- Sarepta Therapeutics (SRPT) stock is under scrutiny due to regulatory risks, clinical evidence, and cash runway concerns surrounding its gene therapy ELEVIDYS. The company is performing significant financing moves, including a convertible notes exchange, and navigating an FDA boxed warning and restricted labeling for ELEVIDYS. While the market presents a "Hold" consensus, there is wide disagreement among analysts on its fair value, driven by uncertainties around ELEVIDYS demand, potential expansion into non-ambulatory use, and FDA tolerance for Duchenne endpoints.

**3. Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings**
- Source: Seeking Alpha | 20251216T164030 | Bullish | Relevance: 100%
- Sarepta Therapeutics (SRPT) stock rose approximately 6% after the HHS announced the inclusion of Duchenne muscular dystrophy and metachromatic leukodystrophy in its recommended newborn screening list. Early diagnosis of these conditions, which typically occurs around age four, could significantly impact patient outcomes.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Wedbush | $32 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Wedbush | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 3 ($0.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 106.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Tudor Investment Cor: 65.7% (+135261.8%)
- Blackrock Inc.: 12.6% (+8.9%)
- Vanguard Group Inc: 10.3% (+18.1%)
- State Street Corpora: 5.1% (+13.0%)
- Erste Asset Manageme: 2.6% (+65.7%)

### Key Risks

1. Valuation stretched: PEG 159.2x requires aggressive growth execution.
2. High short interest (21.6%, 3.4 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 35.8% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 159.25 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (3.0x). Revenue declining -25% YoY, concerning. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.2B |
| Beta | 0.53 |
| 52W Range | $10.42 - $129.84 |
| Short Interest | 21.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 159.25 |
| Forward P/E | 7.3 |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 0.1% to -0.9% (-1.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.9pp (needs >3.0% for momentum thesis). Below SMA200 (0.64x), long-term trend not supportive. RSI neutral at 52. OFD pattern: -FTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.94% (CS: 22) | Neutral |
| RSI_14 | 51.5 | Neutral |
| MACD Histogram | 0.08 | Bullish |
| vs SMA20 | 1.024x | Above |
| vs SMA50 | 1.012x | Above |
| vs SMA200 | 0.642x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $21.14
- **Stop Loss:** $18.40 (13.0% risk)
- **Target:** $23.88 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 394
- **Position Value:** $8,329.16
- **Portfolio %:** 8.33%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-25 (Est: $-0.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.37 | $-0.13 | +65.0% |
| 2025Q2 | $1.16 | $2.02 | +73.9% |
| 2025Q1 | $-0.65 | $-3.42 | -426.6% |
| 2024Q4 | $2.06 | $1.90 | -7.8% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*